Comments

;

Comments on drug pricing transparency interim final rule [CMS-9905-IFC]

Jan 21, 2022

We are pleased that the Biden administration is moving forward with the requirement that insurance plans must report on various data points associated with prescription drug spending. We believe with this greater understanding and transparency of prescription drug costs, you can better implement policies and measures that increase competition, improve prescription drug affordability and access for the American people.

read more

Comments on prescription drug limitations in proposed Oregon Medicaid waiver

Jan 7, 2022

The HIV+Hepatitis Policy Institute write[s] to express our strong opposition to the proposed limits to the prescription drug formulary that have been included as part of Oregon’s 1115 Medicaid Demonstration Waiver. The stated goal of the waiver is to promote greater equity; however, not only do we believe what Oregon is proposing is not legal, but it will have the opposite effect of promoting equity. We urge you to not include these proposals in your waiver submission.

read more

Comments on draft hepatitis federal implementation plan

Nov 19, 2021

We cannot achieve the goal of ending hepatitis without increased funding for the key elements of the strategy, including testing, treating, and vaccination. Increasing resources for hepatitis elimination must be our first priority. While this draft hepatitis federal implementation plan was drafted with current resources in mind, there are areas where we would suggest some strengthening.

read more

Comments in support of hepatitis B universal adult vaccination

Sep 24, 2021

HIV+Hep strongly supports a recommendation for universal hepatitis B vaccination for all adults. The hepatitis B vaccine is safe and effective, with over 1 billion doses administered worldwide and is estimated to have prevented over 310 million infections worldwide between 1990 and 2020. Despite highly effective vaccines, up to 2.4 million people in the United States may be living with chronic hepatitis B, and there are up to 80,000 new cases of hepatitis B each year. With the proper guidance and resources, each new infection is preventable.

read more

Comments recommending PrEP in STI counseling and Well-Woman Preventive Visits

Sep 14, 2021

The HIV+Hepatitis Policy Institute submitted the following comments to the Women’s Preventive Services Institute recommending that HIV preexposure prophylaxis (PrEP) be included for all women at risk of HIV as part of sexually transmitted infection counseling and as part of the Well-Woman Preventive visits, as they update HRSA’s recommended preventive services for women.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest